UNSPSC 51342505: Abacavir succinate

This classification denotes a reverse transcriptase inhibitor, in succinate form, with the molecular formula C14H18N6O.C4H6O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40FH6D8CHK, chemically known as butanedoic acid, compd. with (1s,4r)-4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)-2-cyclopentene-1-methanol (1:1) but more generally known as abacavir succinate, which bears US NIH Compound Identifier 65139. The base compound, abacavir, also appears in sulfate form, and is sometimes combined with lamivudine and zidovudine.

UNSPSC 51342505 Abacavir succinate is a Commodity code that nominally describes a specific antiretroviral pharmaceutical product, but recent state and local solicitations tagged to this code show minimal direct alignment with the code's stated scope. The recent opportunities instead reflect broader pharmaceutical procurement — including emergency medical supplies, generic multi-source drugs, direct-to-manufacturer prescription programs, and over-the-counter products — suggesting either tagging inconsistency or a mismatch between the code's narrow definition and how jurisdictions apply it in practice. State and local buyers under this code span diverse issuing bodies: county health departments (Seminole County, Florida), city fire departments (City of Tampa), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and other members). The work being solicited is primarily pharmaceutical supply provision with varying scope — naloxone and drug deactivation systems for community health, emergency medical and first aid consumables for fire rescue operations, and generic pharmaceuticals for statewide and multi-jurisdictional distribution.

Recent activity clusters in Florida, Texas, and Minnesota, with cooperative purchasing extending across multiple states. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, requiring manufacturers to work through three authorized wholesalers and achieve product availability by May 15, 2026. The City of Tampa posted an IFB (26P00145) for medical and first aid supplies totaling an estimated $700,000.00, due March 13, 2026, and designated as a sheltered market for certified Small Local Business Enterprises with a 5 percent bid discount. Seminole County, Florida solicited naloxone and drug deactivation systems through IFB60459723LAS with an initial due date of July 26, 2023 (record appears dated), and the Texas HHS Commission posted an RFI (HHS0017013) on April 3, 2026 to gather vendor capabilities for a Direct-to-Manufacturer Prescriptions program. The code shows pharmaceutical procurement activity but limited direct purchases of abacavir succinate specifically; vendors pursuing opportunities here should verify tagging accuracy with issuing bodies before bid preparation.